Posted by Tyrone Williams on Feb 13th, 2026
Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year 2025 earnings call, while also reporting...
More of this article »